3 recruiting, 2 unknown, 1 enrolling by invitation, 1 not yet recruiting. 3 Early Phase 1, 3 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 3 | Recruiting 2, Not yet recruiting 1 |
| Phase 1 | 3 | Unknown 2, Enrolling by invitation 1 |
| Phase 2 | 1 | Enrolling by invitation 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Suzhou Immunofoco Biotechnology Co., Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dose-Escalation/Expansion Study of iMagic in Relapsed/Refractory Hematologic Malignancies iMagic Injection (IMV101), iMagic Injection (IMV102) - Relapsed/Refractory Hematologic Malignancies | Early Phase 1 | Not yet recruiting | Suzhou Immunofoco Biotechnology Co., Ltd | 30 | 2026-09-10 | 2026-09-08 |
| A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma IMV102 treatment - Relapsed/Refractory Multiple Myeloma | Early Phase 1 | Recruiting | Suzhou Immunofoco Biotechnology Co., Ltd | 30 | 2026-04-14 | 2026-09-03 |
| Phase I/IIa Clinical Trial of IMC001 in Patients With Advanced Epithelial Solid Tumors. Autologous CAR-T cell injection targeting EpCAM - Epithelial Cancer Patients | Phase 1 / Phase 2 | Enrolling by invitation | Suzhou Immunofoco Biotechnology Co., Ltd | 30 | 2026-03-05 | 2026-06-12 |
| A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma IMV101 treatment - Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | Early Phase 1 | Recruiting | Suzhou Immunofoco Biotechnology Co., Ltd | 30 | 2025-12-29 | 2026-03-30 |
| A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients CAR T cells, Control - Gastric Adenocarcinoma | Phase 3 | Recruiting | Suzhou Immunofoco Biotechnology Co., Ltd | 150 | 2025-08-06 | 2025-10-23 |
| A Phase I Trial to Evaluate the Safety of IMC002 in Advanced Digestive System Tumors IMC002 injection - Advanced Digestive System Tumor | Phase 1 | Unknown | Suzhou Immunofoco Biotechnology Co., Ltd | 18 | 2023-09-07 | 2023-09-28 |
| Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression Claudin 18.2 CAR-T - Gastric Cancer, Pancreatic Cancer | Phase 1 | Unknown | Suzhou Immunofoco Biotechnology Co., Ltd | 30 | 2022-08-08 | 2024-03-06 |
Hematologic Neoplasms (1) · Lymphoma, B-Cell (1) · Multiple Myeloma (1) · Pancreatic Neoplasms (1) · Stomach Neoplasms (1)
China (7)
Jianming Xu, Pro. (1) · Luo Tianhang, MD (1)